keyword
MENU ▼
Read by QxMD icon Read
search

Radioiodine treatment

keyword
https://www.readbyqxmd.com/read/28528452/tumor-suppressor-protein-p53-exerts-negative-transcriptional-regulation-on-human-sodium-iodide-symporter-gene-expression-in-breast-cancer
#1
Madhura G Kelkar, Bhushan Thakur, Abhishek Derle, Sushmita Chatterjee, Pritha Ray, Abhijit De
PURPOSE: Aberrant expression of human sodium iodide symporter (NIS) in breast cancer (BC) is well documented but the transcription factors (TF) regulating its aberrant expression is poorly known. We identify the presence of three p53 binding sites on the human NIS promoter sequence by conducting genome-wide TF analysis, and further investigate their regulatory role. METHODS: The differences in transcription and translation were measured by real-time PCR, luciferase reporter assay, site-directed mutagenesis, in vivo optical imaging, and chromatin immunoprecipitation...
May 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28526978/cytogenetic-biodosimetry-and-dose-rate-effect-after-radioiodine-therapy-for-thyroid-cancer
#2
Igor K Khvostunov, Vladimir A Saenko, Valeri Krylov, Andrei Rodichev, Shunichi Yamashita
This study set out to investigate chromosomal damage in peripheral blood lymphocytes of thyroid cancer patients receiving (131)I for thyroid remnant ablation or treatment of metastatic disease. The observed chromosomal damage was further converted to the estimates of whole-body dose to project the adverse side effects. Chromosomal aberration analysis was performed in 24 patients treated for the first time or after multiple courses. Blood samples were collected before treatment and 3 or 4 days after administration of 2-4 GBq of (131)I...
May 19, 2017: Radiation and Environmental Biophysics
https://www.readbyqxmd.com/read/28516979/interventional-sialendoscopy-for-radioiodine-induced-sialadenitis-quo-vadis
#3
P Canzi, S Cacciola, P Capaccio, F Pagella, A Occhini, L Pignataro, M Benazzo
Salivary gland toxicity is a common adverse effect of radioactive iodine ((131)I) for the treatment of thyroid cancers with a prevalence ranging from 2% to 67% of the (131)I exposed population. Recently, sialendoscopy has been introduced as an attractive diagnostic and therapeutic tool for management of patients with radioiodine-induced sialadenitis that is unresponsive to standard medical treatments. The objective of the current review was to assess the impact of this procedure on outcomes in patients suffering from radioiodine sialadenitis...
April 2017: Acta Otorhinolaryngologica Italica
https://www.readbyqxmd.com/read/28514192/diagnostic-and-treatment-patterns-among-children-adolescents-and-young-adults-with-thyroid-cancer-in-ontario-1992-2010
#4
Jason D Pole, Aleksandra M Zuk, Jonathan Daniel Wasserman
BACKGROUND: Thyroid carcinoma (TC) is rare in young children, with a sharp increase in incidence among adolescents and young adults (AYA), between 15 and 29 years of age. The incidence of TC is increasing worldwide. Limited prospective population-based data are available to describe diagnostic and treatment practices in this age group. This study undertook a population-based review of TC among 0 to 29-year-old individuals in Ontario, Canada, utilizing linked administrative data to describe the demographic and care patterns over nearly two decades...
May 17, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28507839/issues-in-managing-hurthle-cell-carcinoma-of-thyroid-a-case-report
#5
Patricia Tai, Martin Korzeniowski, Evgeny Sadikov, Kurian Joseph, Angus Kirby, Jon Tonita, Aamer Mahmud
A 61-year-old woman noticed a right neck lump in October 2001. Fine needle aspiration showed follicular neoplasm, adenoma versus carcinoma. The ultrasound scan showed a solid mass of maximum dimension of 3.7 cm. She had a right thyroid lobectomy and isthmectomy in January 2002 (first surgery). The tissue specimen showed a 4.5 cm Hurthle cell carcinoma (HCC) with vascular invasion. There were no capsular invasion, extra-thyroidal extension, or margin involvement. A completion left lobectomy (second surgery) was performed two weeks later...
April 14, 2017: Curēus
https://www.readbyqxmd.com/read/28494633/comparison-of-in-clinic-point-of-care-and-reference-laboratory-total-thyroxine-immunoassays-for-diagnosis-and-post-treatment-monitoring-of-hyperthyroid-cats
#6
Mark E Peterson, Mark Rishniw, Graham E Bilbrough, Kate B Cote
Objectives The Catalyst One Chemistry Analyzer (IDEXX Laboratories) is a point-of-care instrument that can measure total thyroxine (TT4) by immunoassay. The aims of this study were to evaluate the analytic performance of the Catalyst TT4 assay in feline sera and to examine agreement of the Catalyst TT4 results with those measured by immunoassay at a veterinary reference laboratory. Methods Assay precision, reproducibility and linearity were evaluated for the Catalyst TT4 assay. For method comparison, TT4 concentrations in serum samples from 157 cats (127 hyperthyroid, 30 radioiodine-treated cats) were analyzed by both in-clinic and reference laboratory methods...
May 1, 2017: Journal of Feline Medicine and Surgery
https://www.readbyqxmd.com/read/28493284/prognostic-value-of-preoperative-anti-thyroglobulin-antibody-in-differentiated-thyroid-cancer
#7
Kwanhoon Jo, Min-Hee Kim, Jeonghoon Ha, Yejee Lim, Sohee Lee, Ja Seong Bae, Chan Kwon Jung, Moo Il Kang, Bong Yun Cha, Dong-Jun Lim
CONTEXT: The coexistence of differentiated thyroid cancer (DTC) and thyroid autoimmune disease could represent a better or worse prognosis. This study investigated the prognostic importance of preoperative anti-thyroglobulin antibody (TgAb) in DTC patients. DESIGN AND PATIENTS: This retrospective hospital-cohort study enrolled 1,171 consecutive DTC patients with preoperative TgAb data, who underwent total thyroidectomy between January 2006 and December 2011. Clinical parameters studied included demographics, primary tumor characteristics, radioiodine therapy, thyroid function tests, preoperative thyroglobulin (Tg) and TgAb levels, and cancer persistence/recurrence...
May 10, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28489758/analysis-of-radioiodine-therapy-and-prognostic-factors-of-differentiated-thyroid-cancer-patients-with-pulmonary-metastasis-an-8-year-retrospective-study
#8
Renfei Wang, Yueqian Zhang, Jian Tan, Guizhi Zhang, Ruiguo Zhang, Wei Zheng, Yajing He
To assess the efficacy of radioiodine therapy (RIT) and investigate the prognostic factors for patients with pulmonary metastasis secondary to differentiated thyroid carcinoma (DTC) through a retrospective study. A total of 80 patients with radioactive iodine-131 (I)-avid pulmonary metastasis from DTC treated with I from 2007 to 2014 at our institution entered the study. Treatment response was mainly measured by two parameters: serum thyroglobulin (Tg) levels and post-therapeutic I whole-body scan (WBS). Treatment variables were assessed for statistical significance using the univariate and multivariate analyses...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28488065/spect-imaging-and-radionuclide-therapy-of-glioma-using-131-i-labeled-buthus-martensii-karsch-chlorotoxin
#9
Wenli Qiao, Lingzhou Zhao, Shan Wu, Changcun Liu, Lilei Guo, Yan Xing, Jinhua Zhao
Gliomas, the most prevalent type of brain tumor in adults, are associated with high rates of morbidity and mortality. Recent studies on (131)I labeled scorpion toxins suggest they can be developed as tumor-specific agents for glioma diagnosis and treatment. This study investigated the potential of (131)I labeled Buthus martensii Karsch chlorotoxin ((131)I-BmK CT) as a new approach for targeted imaging and therapy of glioma. The results showed that (131)I can be successfully linked to BmK CT with satisfactory radiochemical purity and stability and that (131)I-BmK CT markedly inhibited glioma cell growth in a dose and time dependent manner, with significant accumulation in glioma cells in vitro...
May 9, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28486081/cost-effectiveness-of-lenvatinib-sorafenib-and-placebo-in-the-treatment-of-radioiodine-refractory-differentiated-thyroid-cancer
#10
Leslie Wilson, Wei Huang, Linda Chen, Jie Ting, Vicky Cao
BACKGROUND: Lenvatinib (Lenvima®) and sorafenib (Nexavar®) are the two most recently FDA-approved drugs for treating radioiodine-refractory differentiated thyroid cancer (RR-DTC). Both demonstrated superior progression-free survival over placebo in their respective phase III clinical trials. In this study, we compared the cost-effectiveness of the two treatments with placebo from a limited societal perspective. METHODS: A Markov model was developed to estimate the costs and health benefits for treatment of RR-DTC...
May 9, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28474541/the-effect-of-thyroid-related-symptoms-on-long-term-quality-of-life-in-patients-with-differentiated-thyroid-carcinoma-a-population-based-study-in-sweden
#11
Christel Hedman, Therese Djärv, Peter Strang, Catharina Ihre Lundgren
BACKGROUND: Differentiated thyroid cancer (DTC) has a good prognosis but a remaining risk of recurrence, and life-long follow-up as well as medication with levothyroxine may be necessary. The aim of this study was to clarify how thyroid-related symptoms affect health-related quality of life (HRQoL) 14-17 years after diagnosis, in Swedish DTC patients. METHODS: From the all-encompassing population-based Swedish Cancer Registry, 353 patients diagnosed with DTC during 1995-1998 were identified and invited to answer a study-specific questionnaire and the HRQoL questionnaire SF-36, 14-17 years after their diagnosis...
May 5, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28469962/lenvatinib-enhances-the-antitumor-effects-of-paclitaxel-in-anaplastic-thyroid-cancer
#12
Changxin Jing, Zhifei Gao, Rong Wang, Zhao Yang, Bingyin Shi, Peng Hou
Anaplastic thyroid cancer (ATC) is a rare malignancy and has a very poor prognosis due to its aggressive behavior and resistance to treatment. No effective treatment modalities are currently available. Lenvatinib has shown encouraging results in the patients with radioiodine-refractory differentiated thyroid cancer (DTC); however, lenvatinib monotherapy has a relatively low efficacy against ATC. In this study, we assessed the antitumor effects of a combination of lenvatinib and microtubule inhibitor paclitaxel in ATC cells in vitro and in vivo...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28464741/combining-radioiodine-and-external-beam-radiation-therapy-the-potential-of-integrated-treatment-planning-for-differentiated-thyroid-cancer
#13
Lars Tore Gyland Mikalsen, Marius Røthe Arnesen, Trond Velde Bogsrud, Einar Dale, Caroline Stokke
No abstract text is available yet for this article.
June 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28463538/targeted-radionuclide-therapy-an-evolution-toward-precision-cancer-treatment
#14
Hossein Jadvar
OBJECTIVE: This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. CONCLUSION: TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT...
May 2, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28458899/takotsubo-cardiomyopathy-in-amiodarone-induced-hyperthyroidism
#15
Ismael Capel, Elisabet Tasa-Vinyals, Albert Cano-Palomares, Irene Bergés-Raso, Lara Albert, Mercedes Rigla, Assumpta Caixàs
SUMMARY: Takotsubo cardiomyopathy (TC) is an atypical, severe but reversible form of acute heart insufficiency. It typically presents with left ventricular failure, transient apical and mid-segments hypokinesis, absence of significant coronary stenosis and new electrographic abnormalities and/or elevation in serum cardiac enzymes. Although TC ('broken heart syndrome') has classically been associated with emotional trauma, evidence suggests that other precipitants might exist, including iatrogenic and thyroid-mediated forms...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28458457/guidelines-for-the-treatment-of-childhood-onset-graves-disease-in-japan-2016
#16
Kanshi Minamitani, Hirokazu Sato, Hidemi Ohye, Shohei Harada, Osamu Arisaka
Purpose behind developing these guidelines: Over one decade ago, the "Guidelines for the Treatment of Graves' Disease with Antithyroid Drug, 2006" (Japan Thyroid Association (JTA)) were published as the standard drug therapy protocol for Graves' disease. The "Guidelines for the Treatment of Childhood-Onset Graves' Disease with Antithyroid Drug in Japan, 2008" were published to provide guidance on the treatment of pediatric patients. Based on new evidence, a revised version of the "Guidelines for the Treatment of Graves' Disease with Antithyroid Drug, 2006" (JTA) was published in 2011, combined with the "Handbook of Radioiodine Therapy for Graves' Disease 2007" (JTA)...
2017: Clinical Pediatric Endocrinology: Case Reports and Clinical Investigations: Official Journal of the Japanese Society for Pediatric Endocrinology
https://www.readbyqxmd.com/read/28456449/incidence-of-salivary-side-effects-after-radioiodine-treatment-using-a-new-specifically-designed-questionnaire
#17
E Moreddu, K Baumstarck-Barrau, S Gabriel, N Fakhry, F Sebag, O Mundler, C Chossegros, D Taïeb
Sialadenitis is one of the common complications of radioiodine treatment for thyroid malignancy. The aim of this study was to evaluate the prevalence of radioiodine-induced sialadenitis and other side effects by using a self-administered questionnaire. From 1 January 2011 to 31 December 2012 all consecutive patients with a newly-established diagnosis of thyroid cancer who were treated with adjuvant radioiodine at La Timone University Hospital were sent a self-administered questionnaire on salivary complaints that had been specifically designed for this study...
April 26, 2017: British Journal of Oral & Maxillofacial Surgery
https://www.readbyqxmd.com/read/28451906/saul-hertz-md-and-the-birth-of-radionuclide-therapy
#18
EDITORIAL
Frederic H Fahey, Frederick D Grant, James H Thrall
The year, 2016, marked the 75th anniversary of Dr. Saul Hertz first using radioiodine to treat a patient with thyroid disease. In November of 1936, a luncheon was held of the faculty of Harvard Medical School where Karl Compton, PhD, president of the Massachusetts Institute of Technology was invited to give a presentation entitled "What Physics Can Do for Biology and Medicine." Saul Hertz who attended the luncheon spontaneously asked the very pertinent question that perhaps changed the course of treatment of thyroid disease, "Could iodine be made radioactive artificially?" We review the events leading up to the asking of this question, the preclinical investigations by Dr...
December 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28450562/double-targeting-ligands-with-modulated-pharmacokinetics-for-endoradiotherapy-of-prostate-cancer
#19
James M Kelly, Alejandro Amor-Coarasa, Anastasia Nikolopoulou, Till Wüstemann, Peter Barelli, Dohyun Kim, Clarence Williams, Xiwei Zheng, Cong Bi, Bao Hu, J David Warren, David S Hage, Stephen G DiMagno, John W Babich
PSMA-targeted radiotherapy of prostate cancer (PCa) has emerged recently as a promising approach to the treatment of disseminated disease. A small number of ligands have been evaluated in patients, and while early tumor response is encouraging, relapse rate is high, and these compounds localize to the parotid, salivary and lacrimal glands as well as the kidney, leading to dose-limiting toxicities and adverse events affecting quality of life. We envision that dual targeting ligands displaying high affinity for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher therapeutic index and be suitable for treatment of PCa by targeted alpha therapy (TAT)...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28445948/combined-mek-and-pi3-kinase-inhibition-reveals-synergy-in-targeting-thyroid-cancer-in-vitro-and-in-vivo
#20
Oussama ElMokh, Dorothée Ruffieux-Daidié, Matthias A Roelli, Amandine Stooss, Wayne A Phillips, Jürg Gertsch, Matthias S Dettmer, Roch-Philippe Charles
Anaplastic thyroid cancers and radioiodine resistant thyroid cancer are posing a major treat since surgery combined with Iodine131 therapy is ineffective on them. Small-molecule inhibitors are presenting a new hope for patients, but often lead to drug resistance in many cancers. Based on the major mutations found in thyroid cancer, we propose the combination of a MEK inhibitor and a Pi3'-kinase inhibitor in pre-clinical models. We used human thyroid cancer cell lines and genetically engineered double mutant BRAFV600E PIK3CAH1047R mice to evaluate the effect of both inhibitors separately or in combination in terms of proliferation and signaling in vitro; tumor burden, histology, cell death induction and tumor markers expression in vivo...
April 11, 2017: Oncotarget
keyword
keyword
20184
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"